Choosing the optimal adjuvant therapy option for a patient with early-stage HR-positive breast cancer should be a continuous discussion with the patient, according to a presentation at SABCS 2017.
A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.
Results of this randomized, phase 3 study comparing oral gefitinib with IV vinorelbine plus cisplatin revealed the effect of these regimens on disease-free survival in patients with exon 19 deletion or exon Leu585Arg NSCLC.
Patients with stage III NSCLC have a poor median PFS of 8 months despite achieving a good response to the current standard of care of platinum-based double chemotherapy with concurrent radiotherapy.
Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.
Results of a recent study demonstrated overall survival was better among women who underwent breast-conserving surgery vs mastectomy. Furthermore, best overall survival was achieved with adjuvant radiotherapy in the former group and systemic therapy in the latter group.
Partial-breast and reduced-dose radiotherapy was found to be noninferior in preventing local relapse compared with whole-breast radiation therapy in patients with early stage breast cancer with a lower-than-average risk of relapse.
Women with breast cancer who received capecitabine after adjuvant epirubicin had better quality of life (QOL) compared with those who received CMF after adjuvant therapy.
The AR inhibitor fidarestat is effective as adjuvant therapy to enhance doxorubicin sensitivity of colorectal cancer cells and to reduce cardiotoxicity associated with the drug.
Adding a second HER2-blocker to standard care therapy after surgery for HER2-positive breast cancer may be modestly beneficial for some women.
Study also provides evidence supporting an anti-tumor effect associated with a single preoperative dose of pembrolizumab.
Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.
Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.
Adjuvant trastuzumab following chemotherapy significantly improves long-term disease-free survival in women with HER2-positive early breast cancer, according to study data.
Although significant variation in care persists, underuse and misuse of adjuvant endocrine therapy for breast cancer has decreased since 2004.
Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.
The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology have issued a joint consensus guideline update for the use of radiotherapy following mastectomy in patients with breast cancer.
Cognitive decline associated with adjuvant chemotherapy was more likely to occur in older patients, particularly those whose treatment included docetaxel.
A very large retrospective study of patients with stage II colon cancer found adjuvant therapy improves survival, regardless of treatment regimen, patient age, or high-risk pathologic risk features.
Adjuvant chemotherapy administered during and after radiotherapy is feasible for the treatment of patients with high-risk endometrial cancer despite an increased risk of toxicities compared with radiotherapy alone.
Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.
In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.
Most patients with resected non-small cell lung cancer (NSCLC) preferred a collaborative role in decision-making about adjuvant chemotherapy.
The accuracy of axillary staging and of pathologic evaluation of clinically node-positive breast cancer is improved by a new procedure, reducing the need for a more invasive procedure with debilitating complications.
Women are prescribed adjuvant therapies after breast cancer surgery to reduce the risk of cancer recurrence. The effects of these therapies have been assumed to remain constant over time, but a new study suggests the opposite is true.
Use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time and patients treated with the therapy have improved survival over surgery alone, according to study data.
Diffuse optical spectroscopic tomographic imaging (DOST) may be useful in predicting which patients will best respond to chemotherapy used to reduce breast cancer tumors before surgery, according to a new study.
The addition of trastuzumab to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.
Addition of the experimental drug cediranib to standard chemotherapy improves tumor shrinkage and adds a modest improvement in progression-free survival for patients with cervical cancer that has recurred after treatment.
Adding carboplatin and/or bevacizumab to the standard treatment regimen significantly improved pathologic complete response rates in patients with triple-negative breast cancer, according to a new phase 2 study.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|